Quibim partners with European Commission to launch EUCAIM, a federated infrastructure for cancer images data in Europe

24-01-2023 18:14 | 7 dagen geleden Economie

Dit is een origineel bericht van
PR Newswire

-- This partnership is a significant step forward in the fight against cancer. The project will provide a central hub and a federated infrastructure that will link EU-level and national initiatives, hospital networks, and research repositories with cancer images data to help improve early cancer detection and treatment options. -- Quibim will adapt its platform to explore and visualize the imaging and clinical data included in the repository, analyze them, and extract predictive models of patient outcomes. -- Clinicians, researchers and innovators will have cross-border access to an interoperable, privacy-preserving and secure infrastructure for federated, distributed analysis of cancer imaging data. VALENCIA, Spain, Jan. 24, 2023 /PRNewswire/ -- Quibim, a leading medical imaging technology partner, joins the European Commission's European Federation for Cancer Images (EUCAIM) project directing major tasks focused on governance and implementation of the Central Hub and data federation and interoperability. This first-of-its-kind European 'pan-cancer' project aims to create an easy-access to cancer images for clinicians, researchers and innovators to streamline cancer diagnosis, treatment and care.

The infrastructure will be populated by observational studies from 21 clinical sites in 12 EU countries. Moreover, the project will include clinical images and their link with pathology, molecular and laboratory data, expanding to at least 30 distributed data providers from 15 countries by the end of the 4-year project.

Quibim is strategically positioned in EUCAIM as the first company in funding resources, leveraging its experience implementing QP-Discovery®, their imaging and multi-omics platform with cutting-edge technology for transforming imaging data into actionable predictions.

The company will adapt its platform and provide the marketplace to meet the requirements related to the analysis, annotation and exploitation of data and third-party data transfer services through QP-Discovery®. Quibim will lead the EUCAIM Data Preprocessing tools and services contributing to the development of imaging quality control and curation.

In addition, Quibim will be in charge of the image and feature harmonization pipelines to guarantee the minimization of batch effects on the datasets used to train models in the EUCAIM infrastructure, providing tools for the harmonization of feature-based datasets.

This project aligns with the company's primary goal: to turn imaging into a catalyzer of precision medicine. Quibim is a crucial ally in this initiative that aims to promote innovation and the deployment of digital technologies in the treatment and care of cancer to achieve more accurate and faster clinical decision-making, diagnosis, treatment and predictive medicine for cancer patients.

EUCAIM: Europe's most prominent medical image biobank

The EUCAIM project is a pan-cancer initiative that analyzes common elements between different types of tumors to develop more effective cancer therapies.

The project, which has 76 partners, aims to create a digital infrastructure for storing and analyzing cancer images without any identifying patient data. Furthermore, this federated project is the cornerstone of the European Commission initiated European Cancer Imaging Initiative, a flagship of Europe's Beating Cancer Plan (EBCP), which aims to foster innovation and deployment of digital technologies in cancer treatment and care, to achieve more precise and faster clinical decision-making, diagnosis, treatments, and predictive medicine for cancer patients.

The EUCAIM project brings together clinical data providers, researchers, research infrastructures and industry partners with innovative solutions that address the challenges of implementing such a cancer imaging infrastructure. The infrastructure will feature complex and simple oncological anomalies, with over 60 million anonymized cancer image data, and include data from more than 100,000 patients.

EUCAIM will provide access to health professionals, researchers, and innovators worldwide, while prioritizing data privacy and compliance with the General Data Protection Regulation (GDPR). European laws will govern the infrastructure and consider different countries' unique data management regulations. Quibim, with its extensive experience in data de-identification, will also provide tools for image deidentification to guarantee compliance with GDPR and for image annotation by means of segmentation masks.

The project builds upon the results of the work of the "AI for Health Imaging" (AI4HI) Network which consists of 5 large EU-funded projects on big data and Artificial Intelligence in cancer imaging: Chaimeleon, EuCanImage, ProCancer-I, Incisive and Primage.

"As a company, we seek to leverage the power of medical imaging to improve diagnosis of cancer and prediction of patient outcomes. We offer solutions that analyze these images in depth, performing 'virtual' and non-invasive biopsies, extracting critical information to diagnose diseases," points out Angel Alberich-Bayarri, CEO of Quibim. "By participating in the EUCAIM consortium, we seek to provide universal access to this information and make precision medicine available to different healthcare organizations," he concludes.

In addition, the project plans to implement at least 50 artificial intelligence (AI) algorithms, AI tools and clinical prediction models for researchers within the infrastructure by the end of the project. These AI tools can detect diseases before they become evident on radiological images, providing early detection and improving the chances of successful treatment. One example of these tools is Quibim's QP Prostate® and QP Brain® solutions, which can detect prostate and brain diseases by comparing new images with similar images from a database of known diagnoses.

Quibim, through its imaging biomarker panels, can analyze the mechanisms of diseases such as cancer, improve drug programs and monitor treatment efficacy. Using a whole-body analysis approach for each patient, Quibim is driving tissue-agnostic precision medicine, regardless of the type of cancer or where in the body it originated.

EUCAIM is a project co-funded by the European Union.

Photo -

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/quibim-partners-with-european-commission-to-launch-eucaim-a-federated-infrastructure-for-cancer-images-data-in-europe-301729483.html

CONTACT: Laura Peña, laura.pena@bemypartner.es, +34645434602

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Andere persberichten van deze organisatie

Carbon footprint reporting and reduction made easy with Plan Be Eco

WARSAW, Jan. 31, 2023 /PRNewswire/ -- While C-level executives discuss taking climate action to improve the company's reputation and save money, small business owners worry they don't have the right resources to meet carbon footprint reporting regulations. Entrepreneurs need rights tools. According to UN baked SME Climate Hub, 68% of small business owners worry they don't have the right resources to take climate action. Lack of knowledge, money,
10 minuten geleden

Firmenich recognized as one of the world's most dynamic innovators by LexisNexis

Second consecutive year for Firmenich to feature as the only fragrance & taste company in the LexisNexis(®) 'Innovation Momentum 2023: Global Top 100 report' GENEVA, Jan. 31, 2023 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, is proud to announce its inclusion in the 'Innovation Momentum 2023: Global Top 100 report' by LexisNexis(®). The report lists the top 100 leading companies advancing innovative
32 minuten geleden

Plusgrade Acquires UpStay to Expand its Portfolio of Upgrade and Ancillary Revenue Solutions for the Hospitality Industry

-- Plusgrade takes another step forward in becoming the global ancillary revenue powerhouse, by expanding its portfolio further in the thriving hospitality industry -- Acquisition strengthens Plusgrade's unmatched scale across five verticals of the global travel industry -- Plusgrade now expects to generate over US$5 billion in new revenue opportunities for its partners through 2023 MONTREAL, Jan. 31, 2023 /PRNewswire/ -- Plusgrade, the leading p
32 minuten geleden

Postcards From The Edge

Children worldwide call on leaders to make good on promises of universal education in ground-breaking campaign from Education Cannot Wait. NEW YORK, Jan. 31, 2023 /PRNewswire/ -- Through an innovative campaign delivered by the UN's global fund for education in emergencies, Education Cannot Wait (ECW), girls and boys worldwide are sharing "Postcards from the Edge [https://c212.net/c/link/?t=0&l=en&o=3769932-1&h=3276400041&u=https%3A%2F%2Fwww.educa
2 uur geleden

Nobu Hospitality Announces Nobu Hotel, Restaurant, and Residences Al Marjan Island Underscoring Its Regional Presence

NEW YORK, Jan. 31, 2023 /PRNewswire/ -- Nobu Hospitality, the luxury lifestyle brand founded by Nobu Matsuhisa, Robert De Niro and Meir Teper, has signed a management agreement with Enevoria Development FZ-LLC, to develop the Nobu Hotel, Restaurant, and Residences on Al Marjan Island in Ras Al Khaimah. This is the brand's second hotel and residence development in the UAE following the announcement of Abu Dhabi in late 2022. The Nobu Hotel, Restau
2 uur geleden

AV-Comparatives Names Anti-Virus Consumer Product of The Year 2022

The independent security testing laboratory AV-Comparatives consistently tested 17 consumer security products during 2022 and named the Product of the Year. https://www.av-comparatives.org/tests/summary-report-2022/ "AV-Comparatives' 2022 Summary Report provides users with a comprehensive guide to the protection, performance and usability of the tested consumer products." -- Andreas Clementi, Founder and CEO, AV-Comparatives INNSBRUCK, Austria, J
2 uur geleden